Nomura Holdings, Inc.
NYSE:NMRFinancial - Capital Markets
-$0.12 today
- Market cap
- $27.29B
- Beta
- 0.61
- P/E (TTM)
- 0.3
- EPS (TTM)
- $4,986.67
- Dividend yield
- 3.55%
Volume 3.51M
Average 1.75M
NMR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nomura Holdings, Inc.NYSE: NMR
EBITDA · Q1 FY2027 · quarter ended Jun 2026
EBITDA growth accelerates
Q1 FY2027 EBITDA of ¥211.54B rose 32.0% year over year, ahead of the +15.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 66.5% from the prior quarter. Over 3 fiscal years it compounded at +42.3% a year.
Context
- EBITDA amounted to 12.8% of revenue in FY2026, up 0.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of ¥836.03B (+37.5%) for the fiscal year ending Mar 2027, a step up from the +14.0% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- ¥211.54B+66.5% QoQ
- Last fiscal yearMar 2026
- ¥608.09B+14.0% YoY
- LTMJun 2026
- ¥610.47B+15.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.0% | — | — |
| 1 year | +14.0% | +37.5% | +23.5 pp |
| 3-year CAGR | +42.3% | +13.8% | -28.5 pp |
| 5-year CAGR | +13.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
JPY · from the income statement
- Latest · FY2026
- 608.09B JPY
- Year-over-year change
- +14.0%
- 4-year CAGR
- +20.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 608.09B | +14.0% |
| FY2025 | 2025-03-31 | 533.62B | +59.2% |
| FY2024 | 2024-03-31 | 335.19B | +58.9% |
| FY2023 | 2023-03-31 | 210.9B | -26.3% |
| FY2022 | 2022-03-31 | 286.15B | — |
EBITDA vs competitors
How NMR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.3% is the 5th highest of 9, against a peer median of +27.0%.
- EBITDA amounts to 14.1% of revenue for NMR, versus a peer median of 22.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | ¥610.47B JPY | +15.3% | +42.3% | 14.1% | |
| LTM Sep 2026 | $33.01B USD | +41.0% | +14.7% | 26.7% | |
| LTM Sep 2026 | $29.65B USD | +12.9% | +13.7% | 22.9% | |
| LTM Jun 2026 | $21.15B USD | +97.9% | +4.2% | 27.8% | |
| LTM Aug 2026 | $2.35B USD | -37.6% | -23.7% | 18.8% | |
| LTM Sep 2026 | $1.96B USD | +115.2% | +0.4% | 29.3% | |
| LTM Jun 2026 | $1.05B USD | +73.2% | +3.2% | 22.2% | |
| LTM Sep 2026 | $358.38M USD | -23.9% | -13.8% | 10.6% | |
| LTM Mar 2026 | $264.51M USD | +12.1% | +44.8% | 15.4% | |
| Peer median (excluding NMR) | — | +27.0% | +3.7% | 22.5% | |
Competitors are the stored peer set for NMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.37T | 2.3T | 3.97T | 4.51T | 4.76T |
| Cost of Revenue | 230.11B | 1.15T | 2.6T | 2.84T | 2.59T |
| Gross Profit | 1.14T | 1.14T | 1.38T | 1.66T | 2.17T |
| Gross Margin | 83.3% | 49.9% | 34.7% | 36.9% | 45.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 529.51B | 605.79B | 673.52B | 732.39B | 1.37T |
| Operating Expenses | 917.09B | 995.5B | 1.1T | 1.19T | 1.63T |
| Depreciation & Amortization | 59.52B | 61.42B | 61.34B | 61.65B | 68.27B |
| EBITDA | 286.15B | 210.9B | 335.19B | 533.62B | 608.09B |
| EBITDA Margin | 20.8% | 9.2% | 8.4% | 11.8% | 12.8% |
| Operating Income | 226.62B | 149.47B | 273.85B | 471.96B | 539.82B |
| Operating Margin | 16.5% | 6.5% | 6.9% | 10.5% | 11.3% |
| Interest Income | 284.22B | 1.11T | 2.62T | 2.93T | 2.67T |
| Interest Expense | 230.11B | 1.15T | 2.6T | 2.84T | 2.59T |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 226.62B | 149.47B | 273.85B | 471.96B | 539.82B |
| Pre-Tax Margin | 16.5% | 6.5% | 6.9% | 10.5% | 11.3% |
| Income Tax Expense | 80.09B | 57.8B | 96.63B | 124.71B | 165.44B |
| Net Income | 143B | 92.79B | 165.86B | 340.74B | 362.13B |
| Net Margin | 10.4% | 4.0% | 4.2% | 7.6% | 7.6% |
| EPS (Basic) | 46.68 | 30.86 | 54.97 | 115.30 | 123.08 |
| EPS (Diluted) | 45.23 | 29.74 | 52.75 | 111.03 | 118.99 |
| Weighted Avg Shares | 3.06B | 3.01B | 3.02B | 2.96B | 2.94B |
| Weighted Avg Shares (Diluted) | 3.16B | 3.11B | 3.14B | 3.07B | 3.04B |
Nomura Holdings, Inc.
NYSE:NMR
Intrinsic Alpha fair value
Locked
Current Price
$9.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.